
Kishan S Parikh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2392839/publications.pdf Version: 2024-02-01



KICHAN S DADIKH

#	Article	IF	CITATIONS
1	Early Identification of Patients at Risk for Incident Heart Failure With Preserved Ejection Fraction: Novel Approach to Echocardiographic Trends. Journal of Cardiac Failure, 2021, 27, 942-948.	1.7	0
2	Relationship of Nonalcoholic Fatty Liver Disease and HeartÂFailure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2021, 6, 918-932.	4.1	41
3	Pulmonary Hypertension Subtypes and Mortality in CKD. American Journal of Kidney Diseases, 2020, 75, 713-724.	1.9	32
4	Treatment-related biomarkers in pulmonary hypertension patients on oral therapies. Respiratory Research, 2020, 21, 304.	3.6	3
5	Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2020, 75, 299-304.	1.9	8
6	Applications of the Multisensor HeartLogic Heart Failure Monitoring Algorithm During the COVID-19 Global Pandemic. JACC: Case Reports, 2020, 2, 2265-2269.	0.6	9
7	Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor. Chest, 2019, 156, 1176-1186.	0.8	32
8	Echocardiographic Assessment of Right Ventricular Function and Response to Therapy in Pulmonary Arterial Hypertension. American Journal of Cardiology, 2019, 124, 1298-1304.	1.6	13
9	Diverse cardiopulmonary diseases are associated with distinct xenon magnetic resonance imaging signatures. European Respiratory Journal, 2019, 54, 1900831.	6.7	47
10	Characteristics of Acute Heart Failure Hospitalizations Based on Presenting Severity. Circulation: Heart Failure, 2019, 12, e005171.	3.9	15
11	Outcomes of lung disease-associated pulmonary hypertension and impact of elevated pulmonary vascular resistance. Respiratory Medicine, 2019, 150, 126-130.	2.9	12
12	Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension. Scientific Reports, 2019, 9, 4061.	3.3	36
13	Impact of Age on Comorbidities and Outcomes in HeartÂFailure With ReducedÂEjection Fraction. JACC: Heart Failure, 2019, 7, 1056-1065.	4.1	21
14	Cardiac Rehabilitation After VentricularÂAssist Device Implantation. JACC: Heart Failure, 2018, 6, 140-142.	4.1	0
15	Systematic review and meta-analysis of endovascular and surgical revascularization for patients with chronic lower extremity venous insufficiency and varicose veins. American Heart Journal, 2018, 196, 131-143.	2.7	17
16	Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes. Circulation Genomic and Precision Medicine, 2018, 11, e002210.	3.6	8
17	Heart Failure With Preserved Ejection Fraction Expert Panel Report. JACC: Heart Failure, 2018, 6, 619-632.	4.1	103
18	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). American Journal of Cardiology, 2018, 122, 1506-1512.	1.6	16

KISHAN S PARIKH

#	Article	IF	CITATIONS
19	Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization. Circulation, 2017, 135, 2077-2080.	1.6	28
20	Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 69, 1683-1691.	2.8	45
21	Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure. Current Heart Failure Reports, 2017, 14, 529-535.	3.3	2
22	Representativeness of Medicare Participants in the Jackson Heart Study for African American Medicare Beneficiaries. Epidemiology, 2017, 28, 740-746.	2.7	1
23	Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension. Journal of Cardiovascular Pharmacology, 2016, 67, 322-325.	1.9	12
24	Mode of Death After Acute Heart Failure Hospitalization – A Clue to Possible Mechanisms –. Circulation Journal, 2016, 80, 17-23.	1.6	13
25	Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION). American Journal of Cardiology, 2016, 118, 1211-1216.	1.6	11
26	Use of outcome measures in pulmonary hypertension clinical trials. American Heart Journal, 2015, 170, 419-429.e3.	2.7	17
27	PH Grand Rounds: Confronting the Challenge of Sarcoidosis-Associated Pulmonary Hypertension. Advances in Pulmonary Hypertension, 2015, 14, 166-169.	0.1	0
28	Potential Applications of Pharmacogenomics to Heart Failure Therapies. Heart Failure Clinics, 2014, 10, 599-606.	2.1	4